You are viewing the site in preview mode

Skip to main content

Advertisement

Table 2 HPV and CT prevalence among sub-study-1 subjects

From: Impact of HPV vaccination with Gardasil® in Switzerland

  Population (CT n = 327, HPV n = 324) Vaccinees (CT n = 248, HPV n = 245) Non vaccinees (CT n = 77, HPV n = 77) p-value
n pr sd n pr sd n pr sd
CT 15 4.6 1.2 10 4.0 1.3 5 6.5 2.8 0.360
HPV global 95a 29.5 2.5 70 28.6 2.9 25 32.5 5.4 0.567
HPV vaccine 9b 2.8 0.9 6 2.4 1.0 3 3.9 2.2 0.451
  1. Of 327 samples analysed, 327 were informative for Chlamydia trachomatis (CT) and 324 for Human papillomaviruses (HPV)
  2. Two subjects were non informative regarding their vaccine status. They were CT and HPV negative. The 15 CT positive cases were found in 13 HPV positive cases and 2 HPV negative cases
  3. n: number of positive subjects; pr: proportion in %; sd: standard deviation in %; p-value: two-sided Fishers’ p value
  4. aIn total, 217 subject-genotype combinations were found in the 95 HPV positive subjects. Their distribution is shown in fig. 1
  5. bFour subjects were infected by a single vaccine genotype. Five were infected by a single vaccine genotype and by at least another non vaccine genotype